Fairfax Financial Holdings Limited

Fairfax reported second-quarter 2026 operating income from insurance and reinsurance of $1.1 billion (adjusted to an undiscounted basis and before risk margin). Underwriting income was $459 million versus $427 million in Q2 2025, on a combined ratio of 93.1% versus 93.3% a year ago; the comparable IFRS 17 combined ratio was 81.9% versus 84.1%. Interest and dividend income was $737 million, up 11% year over year from $660 million, while profits of associates were $43 million versus $131 million last year. Net investment gains were $769 million, and net earnings were $1.4 billion for the quarter and $2.1 billion for the first six months. Gross premiums written were $9.4 billion, up 4.1% year over year, and book value per share was $1,304.39 at June 30, 2026, up 4.8% from year-end 2025 adjusted for the $15 dividend. Forwardly, management did not give explicit earnings guidance, but reiterated that associate income plus consolidated investments has been discussed as about $1 billion combined and said current performance is running above that prior level. They also said interest and dividend income had an implied run rate of about 5%, while insurance growth is being pressured by softer pricing, especially in North American property.

Peter Clarke’s tone was upbeat but measured, framing the quarter as another strong result driven by underwriting discipline, solid investment income, and meaningful capital actions. He emphasized Fairfax’s diversification by geography and product, saying softer pricing is making growth harder in some North American lines but the company is shifting toward higher-margin business and leaning on international operations, which he said are growing well. He also highlighted long-term partnerships and new transactions as evidence of continued opportunity creation, while noting the Iran conflict and wildfires as active risk situations being monitored.

Amy Sherk walked through the quarter’s key realized items and balance-sheet position, including the $1.9 billion Poseidon sale and $838 million realized gain, the Kennedy-Wilson transaction, and pending deals for Andrew Peller, Sleep Country/Sleep Number, Fairfax India’s IIFL Capital transaction, and the Eurobank/Eurolife/ERBA transactions. She said Fairfax held $2.3 billion of cash and investments at the holding company, had an undrawn $2 billion revolver, and had $4.4 billion of excess fair value over carrying value in noninsurance associates and market-traded consolidated companies. She also noted total debt to total capital, excluding noninsurance companies, increased to 28% from 26.2%, and common shareholders’ equity fell by $234 million to $26 billion, mainly due to share repurchases, dividends, and foreign currency translation losses, offset by $2.1 billion of net earnings attributable to shareholders.

Analysts focused on whether softening pricing is broadening beyond property into casualty, and management said the pressure is still mainly in property, especially in North America, with possible spillover into casualty. Peter Clarke said Fairfax is trimming less attractive business and leaning into international operations, which he said now represent about 20% of total business on Fairfax’s own segment view and closer to 35% when broader international books are included. Questions also covered the Fairfax TRS sale, where management said the stock still looks undervalued and the position remains significant, and leverage/float, where Fairfax said it prioritizes long-term float growth and has been refinancing preferreds into 30-year debt while keeping maturities at least three years out. On associates, management acknowledged quarter-to-quarter volatility but said combined associate and consolidated investment income is running above the roughly $1 billion level previously discussed.